__NUXT_JSONP__("/drugs/Zalifrelimab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"2148321-69-9",chebiId:b,chemicalFormula:b,definition:"A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, zalifrelimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.",fdaUniiCode:"FE7L22H028",identifier:"C126113",preferredName:a,semanticType:"Immunologic Factor",subclassOf:["C128036","C129822"],synonyms:["AGEN-1884","AGEN1884","Anti-CTLA-4 Monoclonal Antibody AGEN1884","ZALIFRELIMAB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FZalifrelimab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Zalifrelimab","","2021-10-30T13:30:41.403Z")));